Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18796276 | 0.84 | HTT (0.40) | HTTL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL20551281 | 0.80 | HTT (0.36) | HTTL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL18796121 | 0.78 | MAP4K4 (0.37) | HTTL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL18796186 | 0.76 | HTT (0.36) | HTTL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL18795982 | 0.75 | MAP4K4 (0.32) | — | |
| SCHEMBL18796156 | 0.72 | SLC22A12 (0.31) | — | |
| SCHEMBL20551046 | 0.68 | CYP11B2 (0.32) | — | |
| SCHEMBL31395414 | 0.64 | CA12 (0.60) | HTTL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL28511624 | 0.63 | L3MBTL1 (0.49) | HTTL3MBTL1GAAMAPTTDP1 | |
| SCHEMBL30194076 | 0.63 | L3MBTL1 (0.49) | HTTL3MBTL1GAAMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200231607-A1 | TRISUBSTITUTEDSILYLHETEROARYLOXYQUINOLINES AND ANALOGUES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-07-23 | — | — | US | disclosed |
| EP-3618632-A1 | TRISUBSTITUTEDSILYLHETEROARYLOXYQUINOLINES AND ANALOGUES | Bayer Aktiengesellschaft (DE) | 2020-03-11 | — | — | EP | disclosed |
| WO-2018202706-A1 | TRISUBSTITUTEDSILYLHETEROARYLOXYQUINOLINES AND ANALOGUES | BAYER AKTIENGESELLSCHAFT (DE) | 2018-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231607-A1 | TRISUBSTITUTEDSILYLHETEROARYLOXYQUINOLINES AND ANALOGUES | PIK3C3, ERG28, DDT | HTT 3813/4885L3MBTL1 1828/4885MEN1 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.